ArticleMolecular oncology2019
Detection of circulating tumor cells in colorectal cancer patients using the GILUPI CellCollector: results from a prospective, single-center study.
Article in Molecular oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- The Use of CellCollector Assay to Detect Free Cancer Cells in the Peritoneal Cavity of Colorectal Cancer Patients: An Experimental Study.Cancer medicine · 2024Trial
- Novel Liquid Biopsy in Gastrointestinal Cancers.Journal of gastroenterology and hepatology · 2026Review
- Exploring metabolic dynamics of cancer metastasis through in vitro models.Discover oncology · 2026Review
- The Future of Tumor Markers: Advancing Early Malignancy Detection Through Omics Technologies, Continuous Monitoring, and Personalized Reference Intervals.Biomolecules · 2025Review
- Numerical Assessment of the Efficiency of a New Minimally Invasive Probe for the Isolation of Circulating Tumor Cells.International journal for numerical methods in biomedical engineering · 2025Article
- Circulating tumor cells: overcoming challenges of detecting a needle in a haystack.Exploration of targeted anti-tumor therapy · 2025Review
- Article
- Dynamic Measurement of a Cancer Biomarker: Towards In Situ Application of a Fiber-Optic Ball Resonator Biosensor in CD44 Protein Detection.Sensors (Basel, Switzerland) · 2024Article
- Latest Research Progress of Liquid Biopsy in Tumor-A Narrative Review.Cancer management and research · 2024Review
- Prospects of liquid biopsy in the prognosis and clinical management of gastrointestinal cancers.Frontiers in molecular biosciences · 2024Review
- The Evolution of Affordable Technologies in Liquid Biopsy Diagnostics: The Key to Clinical Implementation.Cancers · 2023Review
- Circulating tumor cell-derived preclinical models: current status and future perspectives.Cell death & disease · 2023Review
- Network approach in liquidomics landscape.Journal of experimental & clinical cancer research : CR · 2023Review
- Deciphering the Biology of Circulating Tumor Cells through Single-Cell RNA Sequencing: Implications for Precision Medicine in Cancer.International journal of molecular sciences · 2023Review
- Microfluidics engineering towards personalized oncology-a review.In vitro models · 2023Review
- Predictive value of circulating tumor cell counts during the treatment of cancer: interactions with the blood microenvironment.International journal of clinical oncology · 2023Article
- In vivo detection demonstrates circulating tumor cell reduction instead of baseline number has prognostic value in bladder cancer patients receiving neoadjuvant chemotherapy.Cellular oncology (Dordrecht, Netherlands) · 2023Article
- Biosensors for the Isolation and Detection of Circulating Tumor Cells (CTCs) in Point-of-Care Settings.Micromachines · 2023Review
- Review
- Recent Advances in Methods for Circulating Tumor Cell Detection.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The GILUPI CellCollector (CC) is a novel in vivo circulating tumor cell (CTC) detection device reported to overcome the limitations of small blood sample volumes. The aim of this prospective, blinded study was to evaluate the clinical application of the CC and to compare its performance to the CellSearch (CS) system in M0 and M1 colorectal cancer (CRC) patients. A total of 80 patients (31 M0, 49 M1) with CRC were enrolled. CTCs were simultaneously measured in the peripheral blood using CS and the CC, and the results of both assays were correlated to clinicopathological variables and overall survival. The total number of detected CTCs and CTC-positive patients did not significantly differ between both assays. In the M0 patients, the CC detected CTCs more frequently than CS. There was no significant difference in total CTC numbers detected with the CC between M0 and M1 patients. In addition, no significant correlation with clinicopathological parameters or overall survival was observed with CC CTCs. In contrast, detection of CTCs with CS was significantly correlated with Union for International Cancer Control stage and reduced overall survival. There was no correlation between CTCs detected by the CC and the CS system. Using in silico analysis, we estimate that CC screens a volume of 0.33-18 mL during in vivo application, in contrast to much higher volumes reported elsewhere. In conclusion, while being safe and easy to use, the CC did not outperform CS in terms of CTC yield or sensitivity. While CTC detection in M0 CRC patients was significantly increased with the CC, the clinical relevance of these CTCs appears inferior to the cells identified by the CS system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.